ERBB2 and neoplasm: Indeed, ctDNA levels correlate with early tumor response and can predict resistance to anti-EGFR, anti-HER2, and BRAF-targeted therapies, helping to identify patients who may benefit from reintroducing anti-EGFR therapy after resistant clones have disappeared.